A Phase 1 interventional study of AZD2281 and Bevacizumab in Neoplasm Metastasis, sponsored by AstraZeneca. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-14.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing olaparib in Neoplasm Metastasis — 5 open to participants now, 7 under way, none of them phase 3. olaparib · Neoplasm Metastasis.
Among the 13 studies testing olaparib in Neoplasm Metastasis, this one is the 9th largest by enrollment, is one of 4 that started in 2008, is one of 8 in phase 1, and was the 3rd registered.
4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →5 of the 13 studies testing olaparib in Neoplasm Metastasis are open now, in 4 countries. Recruiting first, the newest first:
Mary D Chamberlin · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Oslo University Hospital · Sites in Norway
Ages 16+
Centre Leon Berard · Sites in France
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 28 across the 13 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 7 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Neoplasm Metastasis by AstraZeneca: 6 open now, 23 under way, 14 of them phase 3. Of 36 finished, 16 (44%) have results posted.
Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 50th largest by enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2008, is one of 19 in phase 1, and was the 13th registered.
AstraZeneca’s Neoplasm Metastasis studies by the year they started, since 1998.
1 of the studies testing olaparib in Neoplasm Metastasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585958National Cancer Institute (NCI)Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing olaparib in Neoplasm Metastasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Neoplasm Metastasis:
This tab as a report to print or save as PDF → With an account.
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation Study 50, 100, 200, 400 mg
Drug: AZD2281 · Drug: Bevacizumab
Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
Also known as: Olaparib
IV administration10 mg/kg every 14 days
Also known as: Avastin
safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with Bevacizumab to patients with advanced solid tumours by assessment of adverse events, vital signs, ECG, clinical chem, haematology, urinalysis and phys exam
Time frame: various timepoints.
To compare exposure to AZD2281 when given alone and in combination with Bevacizumab, by assessment of appropriate derived PK parameters
Time frame: various timepoints.
The record gives a start of Jun 2008, a primary completion of Mar 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib